

# Hematologic Neoplasms

[View the current Hematologic Neoplasms InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Hematologic_Neoplasms.html) ([PDF](#))

([http://www.bioportfolio.com/indepth/Hematologic\\_Neoplasms.html](http://www.bioportfolio.com/indepth/Hematologic_Neoplasms.html)) - Regularly Updated.

## Recent Publications on Hematologic Neoplasms:



- [p38 Mitogen-activated protein kinase and hematologic malignancies.](#)  
*CONTEXT: p38 mitogen-activated protein kinase (MAPK) signaling has been...*18th November, 2009  
Department of Pathology, The Methodist Hospital and The Methodist Hospital- Arch Pathol Lab Med. 2009 Nov;133(11):1850-6.
- [\[Research progress of zebrafish as a model system for hematological neoplasms\]](#)  
*Zebrafish is becoming a powerful vertebrate model for studies of human...*13th November, 2009  
Department of Hematology, RenJi Hospital and Laboratory of Leukemia,- Yi Chuan. 2009 Sep;31(9):889-95.
- [Neonatal intravenous injection of a gammaretroviral vector has a low incidence of tumor induction in mice.](#)  
*Neonatal intravenous injection of gammaretroviral vectors (gamma-RVs) with...*11th November, 2009  
Department of Internal Medicine, Washington University School of Medicine,- Hum Gene Ther. 2008 Nov;19(11):1317-23.
- [Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly.](#)  
*The incidence of cancers increases with advancing age. To improve the...*11th November, 2009  
Department of Hematology, Tokyo Metropolitan Geriatric Hospital,- Geriatr Gerontol Int. 2009 Jun;9(2):115-23. ([DOI Direct Link](#))
- [TGF-beta enforces senescence in Myc-transformed hematopoietic tumor cells through induction of Mad1 and repression of Myc activity.](#)  
*Inhibition of tumor growth factor (TGF)-beta-mediated cell cycle exit is...*7th November, 2009  
Department of Plant Biology and Forest Genetics, Uppsala Genetic Center,- Exp Cell Res. 2009 Nov 1;315(18):3099-111. Epub 2009 Sep 17. ([DOI Direct Link](#))
- [Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies.](#)  
*Many patients who receive co-treatment with GnRH agonists (GnRH-a) during...*5th November, 2009  
Institut Clinic de Ginecologia, Obstetricia i Neonatologia, Hospital- Fertil Steril. 2009 Oct;92(4):1260-3. Epub 2009 Sep 3. ([DOI Direct Link](#))
- [Venous thromboembolism in the hematologic malignancies.](#)  
*Patients with hematologic malignancies are at high risk of thrombotic or...*3rd November, 2009  
Division of Immunohematology and Transfusion Medicine, Department of- J Clin Oncol. 2009 Oct 10;27(29):4848-57. Epub 2009 Sep 14. ([DOI Direct Link](#))
- [Prevention of thrombosis in ambulatory patients with cancer.](#)

*Cancer patients with solid tumors or hematologic malignancies receive most...*3rd November, 2009  
Department of Oncology, McMaster University and Juravinski Cancer Centre,- J Clin Oncol. 2009 Oct 10;27(29):4885-8. Epub 2009 Sep 14. ([DOI Direct Link](#))

- [Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies.](#)  
*Telomeres are composed of long arrays of TTAGGG repeats and associated...*24th October, 2009  
Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia,- Ann N Y Acad Sci. 2009 Sep;1176:178-90. ([DOI Direct Link](#))
- [Natural genetic diversity as a means to uncover stem cell regulatory pathways.](#)  
*Natural genetic diversity is a largely untapped reservoir for use in the...*24th October, 2009  
Markey Cancer Center, University of Kentucky, Lexington, Kentucky- Ann N Y Acad Sci. 2009 Sep;1176:170-7. ([DOI Direct Link](#))
- [Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can.](#)  
*Inhibition of tumor growth factor (TGF)-beta-mediated cell cycle exit is...*23rd October, 2009  
- Blood. 2009 Sep 17;114(12):2564-6. ([DOI Direct Link](#))
- [Normal and pathological V\(D\)J recombination: contribution to the understanding of human lymphoid malignancies.](#)  
*The majority of haematological cancers involve the lymphoid system. They...*2nd October, 2009  
Centre d'Immunologie de Marseille-Luminy, Universite d'Aix Marseille,- Adv Exp Med Biol. 2009;650:180-94.
- [Ocular findings after allogeneic hematopoietic stem cell transplantation.](#)  
*OBJECTIVE: To study the incidence, causes, and outcome of major ocular...*25th September, 2009  
The Eye Center and The Eye Foundation for Research in Ophthalmology,- Ophthalmology. 2009 Sep;116(9):1624-9. ([DOI Direct Link](#))
- [Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.](#)  
*Bone marrow examination has become increasingly important for the...*24th September, 2009  
Medical College of Virginia Hospitals of Virginia Commonwealth University,- J Clin Lab Anal. 2009;23(5):259-307. ([DOI Direct Link](#))
- [A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms.](#)  
*BACKGROUND: Alterations in the DNA methylation pattern are a hallmark of...*15th September, 2009  
Institute of Human Genetics, Christian-Albrechts University, Kiel,- PLoS One. 2009 Sep 11;4(9):e6986. ([DOI Direct Link](#))

## Hematologic Neoplasms Patents:



- 7449303- [Use of JAG2 expression in diagnosis of plasma cell disorders](#)
- 5734039- [Antisense oligonucleotides targeting cooperating oncogenes](#)
- 5670477- [Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents](#)
- 5670317- [Diagnostic test for the desmoplastic small round cell tumor](#)
- 5663197- [2-\(1-hydroxyethyl\)-5-hydroxynaphtho\[2,3-b\]furan-4,9-dione and antitumor agents comprising this compound](#)
- 5618709- [Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the](#)

## [STK-1 protein](#)

- 5612212- [Selective inhibition of cell proliferation by vav antisense oligonucleotides](#)
- 5604198- [Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents](#)
- 5424296- [2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma](#)
- 5149527- [Immunopotentiating protocol for chemotherapy-responsive tumors](#)
- 5098890- [Antisense oligonucleotides to c-myc proto-oncogene and uses thereof](#)
- 5064823- [Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers](#)
- 4996145- [Method for detecting immune-mediated cytotoxicity](#)
- 4950477- [Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes](#)
- 5736326- [Method of detecting resistance to chemo therapeutic agents in cancer patients](#)
- 5807743- [Interleukin-2 receptor gamma-chain ribozymes](#)
- 5872242- [Antisense oligonucleotide inhibition of ras](#)
- 7196184- [Double-stranded RNA \(DSRNA\) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene](#)
- 6784290- [Antisense oligonucleotide inhibition of ras](#)
- 6693083- [Conjugates targeted to the interleukin-2 receptor](#)
- 6410312- [huBUB3 gene involved in human cancers](#)
- 6383792- [RAQ genes and their uses](#)
- 6348352- [Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene](#)
- 6251866- [Conjugates targeted to the interleukin-2 receptor](#)
- 6191168- [Methods for the use of nonprotein amino acids as therapeutic agents](#)
- 6165739- [Multiple simultaneous testing media](#)
- 6143522- [Methods of modulating apoptosis](#)
- 6117848- [Antisense oligonucleotide inhibition of ras](#)
- 6017710- [RAQ genes and their uses](#)
- 5989849- [Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods](#)
- 4499183- [Detecting intracellular antigens in swelled and fixed cells with labeled antibody](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

